Home Health & Wellness Covid Vaccines Reduce Post-Infection Cardiac and Thromboembolic Complications, Study Finds

Covid Vaccines Reduce Post-Infection Cardiac and Thromboembolic Complications, Study Finds

Reading Time: 2 minutes

A recent multinational study has revealed that Covid vaccination significantly reduces the risk of post-infection thromboembolic and cardiovascular complications. Conducted across three European countries, the research provides compelling evidence supporting the protective benefits of vaccines beyond the initial prevention of Covid. The findings were published in the journal Heart.

Nria Mercadé-Besora and her team used data from four population-based healthcare datasets in the UK, Spain, and Estonia for the study. To find out how Covid vaccines affect the risk of venous thromboembolism (VTE), arterial thrombosis/thromboembolism (ATE), and other heart problems up to a year after getting SARS-CoV-2, the researchers looked at other factors as well.

The findings indicate that Covid vaccination is associated with a substantial reduction in the risk of thromboembolic and cardiac events during the acute phase of Covid. Specifically, the risk reduction ranged between 45% and 81% for these events within the first 30 days of infection. In the post-acute phase, which extends from 31 to 365 days after infection, the risk reduction for these events was somewhat lower, ranging from 24% to 58%.

The study observed a significant decrease in the risk of VTE in vaccinated individuals across different time frames post-infection. The meta-analytic subdistribution hazard ratios (sHR) for acute VTE were 0.22 (95% CI, 0.17–0.29). For the post-acute phase, the sHRs were 0.43 (31–90 days), 0.53 (91–180 days), and 0.50 (181–365 days).

Similarly, the risk of ATE, including ischaemic stroke and myocardial infarction, was reduced in vaccinated groups. The sHR for acute ATE was 0.53 (95% CI, 0.44–0.63), with reductions persisting in the post-acute phase.

The risk of heart failure and other severe cardiac complications also showed a notable reduction in vaccinated individuals, especially during the acute phase of Covid.

The study also compared the effects of different Covid vaccines, namely Oxford/AstraZeneca’s ChAdOx1 and BioNTech/Pfizer’s BNT162b2. The results indicated a stronger protective effect of the BNT162b2 vaccine against VTE in the acute phase compared to ChAdOx1. But no significant differences were observed between the two vaccines for post-acute VTE or other cardiac outcomes .

These findings align with previous research suggesting the benefits of Covid vaccination in mitigating severe post-infection complications. While some studies have noted potential risks associated with vaccination, such as myocarditis, particularly with mRNA vaccines, the overall protective effect against severe Covid complications is substantially greater.

For instance, a study conducted in England indicated a higher risk of myocarditis following SARS-CoV-2 infection than after vaccination. This supports the view that the benefits of vaccination far outweigh the risks.

The study’s strengths lie in its large, representative datasets and robust methodological approach, including the use of a staggered cohort design and propensity score weighting to minimise bias. However, limitations include the observational nature of the study and the potential for residual confounding despite the use of negative control outcomes and empirical calibration.

© Copyright 2014–2034 Psychreg Ltd